Head to Head Survey: SAB Biotherapeutics (NASDAQ:SABS) versus Tonix Pharmaceuticals (NASDAQ:TNXP)

Tonix Pharmaceuticals (NASDAQ:TNXP) and SAB Biotherapeutics (NASDAQ:SABS) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, risk and profitability.

Profitability

This table compares Tonix Pharmaceuticals and SAB Biotherapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tonix Pharmaceuticals	-548.64%	-68.99%	-61.31%
SAB Biotherapeutics	N/A	-6.74%	-6.06%

Institutional & Insider Ownership

82.3% of Tonix Pharmaceuticals shares are held by institutional investors. Comparatively, 7.8% of SAB Biotherapeutics shares are held by institutional investors. 2.0% of Tonix Pharmaceuticals shares are held by insiders. Comparatively, 7.4% of SAB Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Tonix Pharmaceuticals and SAB Biotherapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tonix Pharmaceuticals	1	0	0	2	3.00
SAB Biotherapeutics	1	1	9	0	2.73

Tonix Pharmaceuticals currently has a consensus target price of $24.50, suggesting a potential upside of 204.42%. SAB Biotherapeutics has a consensus target price of $12.00, suggesting a potential upside of 286.47%. Given SAB Biotherapeutics’ higher probable upside, analysts plainly believe SAB Biotherapeutics is more favorable than Tonix Pharmaceuticals.

Earnings & Valuation

This table compares Tonix Pharmaceuticals and SAB Biotherapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tonix Pharmaceuticals	$13.11 million	10.53	-$124.02 million	($12.94)	-0.62
SAB Biotherapeutics	$1.32 million	214.03	$13.27 million	($1.30)	-2.39

SAB Biotherapeutics has lower revenue, but higher earnings than Tonix Pharmaceuticals. SAB Biotherapeutics is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Tonix Pharmaceuticals has a beta of 1.78, meaning that its share price is 78% more volatile than the S&P 500. Comparatively, SAB Biotherapeutics has a beta of 0.58, meaning that its share price is 42% less volatile than the S&P 500.

Summary

SAB Biotherapeutics beats Tonix Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company’s priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company’s rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company’s infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes. Further, the company develops SAB-176, a multivalent, broadly neutralizing – human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.